Authors

Yazmin Odia, Miami Cancer InstituteFollow
Doured Daghistani, Miami Cancer InstituteFollow
Zuanel Diaz, Miami Cancer InstituteFollow
Matthew Hall, Miami Cancer InstituteFollow

Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy

Publication Date

9-13-2022

Content Type

Article

PubMed ID:

36382108

Additional Authors:

Additional authors and institutional affiliations

Citation

Gardner, S. L., Tarapore, R. S., Allen, J., McGovern, S. L., Zaky, W., Odia, Y., Daghistani, D., Diaz, Z., Hall, M. D., Khatib, Z., Koschmann, C., Cantor, E., Kurokawa, R., MacDonald, T. J., Aguilera, D., Vitanza, N. A., Mueller, S., Kline, C., Lu, G., Allen, J. E., … Khatua, S. (2022). Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. Neuro-oncology advances, 4(1), vdac143. https://doi.org/10.1093/noajnl/vdac143